Peak Bio, Inc. (PKBOW)
PKBOW Stock Price Chart
Explore Peak Bio, Inc. interactive price chart. Choose custom timeframes to analyze PKBOW price movements and trends.
PKBOW Company Profile
Discover essential business fundamentals and corporate details for Peak Bio, Inc. (PKBOW) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
2 Nov 2022
Employees
6.00
Website
https://peak-bio.comCEO
Hoyoung Huh
Description
Peak Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics addressing unmet needs in the areas of oncology and inflammation. The company's proprietary toxin, PH-1 or Thailanstatin, a spliceosome modulator is being used to generate its first pipeline of novel ADC product candidates to address unmet needs in cancer patients. Its lead product candidate, PHP-303, is a small molecule awaiting Phase II dose clinical study in the orphan disease Alpha1 anti-trypsin deficiency (AATD). The company is based in Palo Alto, California.
PKBOW Financial Timeline
Browse a chronological timeline of Peak Bio, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Earnings released on 30 Jun 2023
EPS came in at -$0.30 .
PKBOW Stock Performance
Access detailed PKBOW performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.